Molecular Diagnostics at Abbott


The information contained in this website has been compiled by CodeMap, L.L.C. to assist Abbott customers. CodeMap, L.L.C. remains solely responsible for its content. The information provided is for general educational purposes only and may not be conclusive or exhaustive. Recent changes in applicable law, regulations and interpretations may not be reflected in the information contained herein. For technical questions, please contact CodeMap.

For other reimbursement questions, please call (704) 253-5086 or email eric.moore@abbott.com.

Fee schedules do not reflect 2% Payment Adjustment (Sequestration). Click here for more information.


      FISH
            AneuVysion®
      RealTime PCR
            RealTime CT/NG
            RealTime CMV
            RealTime HBV
            RealTime HCV
            RealTime HCV Genotype II
            RealTime HIV-1
            RealTime SARS-CoV-2

      Sequencing
            ViroSeq HIV-1 Genotyping System

      Alinity m
            Alinity m CMV Assay
            Alinity m EBV Assay
            Alinity m HBV Assay
            Alinity m HCV Assay
            Alinity m HIV Assay
            Alinity m HPV Assay
            Alinity m MPXV Assay
            Alinity m Resp-4-Plex
            Alinity m SARS-CoV2 Assay
            Alinity m STI Assay

      FISH
            PathVysion® HER-2 DNA Probe Kit
            UroVysion®
            Vysis ALK Break Apart FISH Probes Kit
            Vysis CLL FISH Probe Kit
            Vysis EGR1 FISH Probes Kit

      RealTime PCR
            RealTime IDH1®
            RealTime IDH2®
RealTime SARS-CoV-2
RealTime SARS-CoV-2



U.S. Medicare Part B Reimbursement for
Fees Reflect 2024 CMS Medicare Fee Schedules


The Abbott RealTime SARS-C0V-2 assay is an Emergency Use Authorization (EUA) test authorized by the U.S. FDA for use by authorized laboratories, using real-time (RT) polymerase chain reaction (PCR) technology for the qualitative detection of nucleic acids from the SARS-CoV-2 virus and diagnosis of SARS-CoV-2 virus infection from individuals meeting CDC clinical and/or epidemiological testing criteria. The SARS-CoV-2 assay is not FDA cleared or approved.

Effective FOR DATES OF SERVICE ON OR AFTER May 12, 2023, providers should submit claims for COVID-19 AMPLIFIED PROBE METHOD TESTS, INCLUDING high throughput assays, with CPT code 87635. The HCPCS CODES FOR high throughput ASSAYS U0003 and U0005 were discontinued EFFECTIVE FOR DATES OF SERVICE ON OR AFTER May 12, 2023 along with the PHE termination.

For more information, please see Laboratories: CMS Flexibilities to Fight COVID-19



Procedure Code: 87635   CCI   MUE  

Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), amplified probe technique

Medicare Fee Schedule Amount: $ 51.31





LOINC Codes-Updated 7/18/2024

Under the MolDx program, certain molecular tests require a Z-Code(TM) identifier in addition to the appropriate CPT code. Services within the scope of this program require the Z-Code(TM) to be submitted as additional information at the time of claim submission in order to be fully adjudicated. Laboratories performing these molecular tests may be required to register with the MolDx program for each molecular pathology test they furnish. For more information on the MolDx program, registration and covered procedures, please click here: https://www.palmettogba.com/palmetto/MolDX.nsf

The information contained in this website has been compiled by CodeMap, L.L.C. to assist Abbott customers in preparing and submitting claims to Federal health care programs and CodeMap, L.L.C. remains solely responsible for its content. The information provided is for general educational purposes only and may not be conclusive or exhaustive. Recent changes in applicable law, regulations and interpretations may not be reflected in the information contained herein.

Abbott assumes no responsibility for omissions or errors contained in this website. Abbott does not guarantee that the use of any information provided herein will result in coverage or payment by Federal health care programs at any particular level. Many factors affect Federal health care program reimbursement, not all of which may be described in the information provided. Website users are encouraged to seek individual legal and/or coding guidance. IN PROVIDING THIS WEBSITE, ABBOTT MAKES NO WARRANTIES, EXPRESS, IMPLIED OR STATUTORY, INCLUDING, BUT NOT LIMITED TO, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND/OR NON-INFRINGEMENT.

Abbott is not responsible for any actions taken by website users in billing Medicare or Medicaid for Abbott products, equipment or devices, including but not limited to, any billing and/or coding errors. Website users rely on the information contained in this website at their own risk and should check with the individual Federal health care program contractors to verify coverage, coding and payment. As a courtesy to its customers, Abbott provides the most accurate and up-to-date information available, but it is subject to change and interpretation. The customer is ultimately responsible for determining the appropriate codes, coverage, and payment policies for individual patients. Abbott does not guarantee third party coverage or payment for our products or reimburse customers for claims that are denied by third party payors.

This website is a private website and is not associated, endorsed or authorized by the Department of Health and Human Services, the Center for Medicare and Medicaid Services or any other public or government organization or agency. © 2022 Abbott. All rights reserved. All trademarks referenced are trademarks of either the Abbott group of companies or their respective owners.

CPT copyright 2023 American Medical Association. All rights reserved.

12/07/2024 02:52:56